Skip to main content
SpringerLink
Log in

Schwerpunkt Nierenzellkarzinom

Aktuelle zielgerichtete Therapie des RCC

  • schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Zahlreiche Neuzulassungen in den vergangenen Monaten haben zu Fortschritten in der Therapie des lokal fortgeschrittenen und metastasierten Nierenzellkarzinoms (RCC) geführt. Derzeit stehen neben drei immunonkologischen zehn weitere zielgerichtete Substanzen zur Verfügung. Die folgende Übersicht liefert einen aktuellen Überblick über die zielgerichtete Behandlung des RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32(18):1968–76

    Article  CAS  Google Scholar 

  2. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006;76:217–57

    Article  CAS  Google Scholar 

  3. Escudier B et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2019; http://doi.org/10.1093/annonc/mdz056

    Google Scholar 

  4. Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81

    Article  CAS  Google Scholar 

  5. Heng DY et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8

    Article  Google Scholar 

  6. Ravaud A et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med, 2016;375(23):2246–54

    Article  CAS  Google Scholar 

  7. Choueiri TK et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591–7

    Article  CAS  Google Scholar 

  8. Choueiri TK et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814–23

    Article  CAS  Google Scholar 

  9. Motzer RJ et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82

    Article  CAS  Google Scholar 

  10. Motzer RJ et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland

    Stefanie Zschäbitz

Authors
  1. Stefanie Zschäbitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Zschäbitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zschäbitz, S. Aktuelle zielgerichtete Therapie des RCC. Info Onkol. 22, 10–12 (2019). https://doi.org/10.1007/s15004-019-6419-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6419-y

Search

Navigation